Hofseth BioCare Reports Q1 2025 Revenue Growth

Hofseth Biocare ASA ( (HOFBF) ) has released its Q1 earnings. Here is a breakdown of the information Hofseth Biocare ASA presented to its investors.

Hofseth BioCare ASA is a company specializing in the production of sustainable, clinically validated marine ingredients, operating within the biotechnology sector with a focus on health and nutrition.

In the first quarter of 2025, Hofseth BioCare ASA reported a 15% year-over-year increase in revenues, reaching NOK 60.9 million, despite facing challenges such as a prolonged maintenance shutdown and pressure on commodity fish oil pricing. The company has focused on expanding its higher-value health-focused segments to offset these challenges.

Key financial highlights include a 66% growth in the human B2B segment, driven by demand for products like OmeGo®, ProGo®, and NT-II™ in Europe and Asia. The company also achieved a record production output at its Midsund facility and made significant advances in its pharmaceutical research, including promising developments in prostate cancer and asthma treatments. Furthermore, Hofseth BioCare has initiated an expansion project at its Berkåk facility to triple production capacity, supported by a EUR 5 million loan from Symrise.

Despite a negative EBITDA of NOK 19.9 million, the company improved its cash flow from operations and secured additional financing, increasing its cash and cash equivalents to NOK 71.9 million by the end of Q1 2025. The company remains optimistic about its growth prospects, with plans for new product launches and continued expansion in key markets.

Looking ahead, Hofseth BioCare is well-positioned to accelerate growth and improve profitability, with a robust pipeline of clinical and product development initiatives. The company’s commitment to delivering natural, sustainable marine ingredients continues to differentiate it in the global market.